Event Contact
Katrina Shaw
Speaker Information
Graham Colditz, MD, DrPH
Graham Colditz is the Niess-Gain Professor at WashU Medicine and Associate Director for prevention and control at Siteman Cancer Center. He is highly cited for his research and has received numerous national awards for his contributions to cancer prevention. He is also the Co-Founder of Prognosia Inc.
He has a long history of translating public health research to prevention and has developed a range of models integrating epidemiologic data to estimate risk and guide prevention.
With Dr. Jiang he has focused on developing and applying AI technology for breast cancer risk prediction. Prognosia Breast has received the Breakthrough Device Designation from the FDA.
Shu (Joy) Jiang, PhD
Dr. Jiang is an Associate Professor in the Division of Public Health Sciences and Surgery at Washington University School of Medicine. She is also the Co-Founder of Prognosia Inc.
Dr. Jiang has made major contributions to original methods research with a particular focus on breast cancer risk prediction using medical images and is passionate about translational research from bench to clinic.
Her work has been recognized and funded by the National Institute of Health where she was awarded the NIH MERIT Award in 2021 and was recognized as a member of the Forbes 30 under 30 in Healthcare in 2023.
This year, her AI technology for breast cancer risk prediction, Prognosia Breast, has received the Breakthrough Device Designation from the FDA.
Dave Smoller, PhD
Dave is a General Partner at Cultivation Capital Life Sciences Fund, a venture fund focused on life science investing with 26 portfolio companies in therapeutics, diagnostics, healthcare IT, research tools, and agriculture. He is also an Entrepreneur in Residence at St. Louis BioGenerator, the investment arm of BioSTL.
Dave co-founded Solis Agrosciences in 2022 and, in partnership with Telegraph Hill Partners, co-founded Panome Bio. In 2016, he co-founded Canopy Biosciences, which was acquired by Bruker Corporation in 2020.
Previously, Dave founded SAGE Labs in 2013, a leader in developing and maintaining transgenic rodents. He served in leadership roles at Sigma-Aldrich from 2004 to 2012, including Chief Scientific Officer and President of the Research Biotech Business Unit. Before that, he was President and CEO of ProteoPlex, which he sold to EMD Biosciences in 2003. In 1992, Dave founded Genome Systems, which he sold to Incyte Corporation in 1996.
Dave holds a Doctorate in Molecular Biology and a Bachelor’s degree in Biology from Emory University. He completed postdoctoral fellowships at Washington University and Monsanto Corporation.
